Lung Marker Control

The CanAg CEA EIA kit is intended for the quantitative determination of the cancer associated antigen CEA in serum.

The CYFRA 21-1 EIA kit is intended for the quantitative determination of soluble cytokeratin 19 fragments in human serum. The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in lung cancer patients. Serial testing for patient CYFRA 21-1 assay values should be used in conjunction with other clinical methods used for monitoring lung cancer.

The CanAg ProGRP EIA kit is an immunoassay for the quantitative determination of ProGRP in serum. The CanAg ProGRP assay is to be used as an aid in the differential diagnosis and in monitoring disease progression during the course of disease and treatment in small cell lung cancer patients. Testing for patient proGRP assay values should be used in conjunction with other clinical methods used in the management of patients with small cell lung cancer.

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of carcinoembryonic antigen (CEA) in serum or plasma.

Immunoreaction cartridges for in vitro diagnostic use with the LUMIPULSE G System for the quantitative measurement of cytokeratin subunit 19 fragment (CYFRA) in serum or plasma.

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Pro-gastrin-releasing peptide [ProGRP (31-98)] in serum or plasma.